Notice of Meeting, 27835-27836 [E8-10753]
Download as PDF
Federal Register / Vol. 73, No. 94 / Wednesday, May 14, 2008 / Notices
(6), Title 5, U.S.C., and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Section
10(d) of Public Law 92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services, and the Director, CDC, concerning
the scientific and technical merit of grant and
cooperative agreement applications received
from academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct specific
injury research that focuses on prevention
and control.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of cooperative agreement
applications submitted in response to Fiscal
Year 2008 Requests for Applications related
to the following individual research
announcement: CE08–004, Translation
Research to Prevent Motor Vehicle-Related
Crashes and Injuries to Teen Drivers and
Their Passengers (R01).
Agenda items are subject to change as
priorities dictate.
National Center for Injury Prevention and
Control determines that agency business
requires its consideration of this matter on
less than 15 days notice to the public and
that no earlier notice of this meeting was
possible.
Contact Person for More Information: J.
Felix Rogers, PhD, M.P.H., Telephone (770)
488–4334, NCIPC/ERPO, CDC, 4770 Buford
Highway, NE., M/S F62, Atlanta, Georgia
30341–3724.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: May 8, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–10747 Filed 5–13–08; 8:45 am]
BILLING CODE 4163–18–P
Status: The meetings will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5,
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Section 10(d) of Public Law
92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services, and the Director, CDC, concerning
the scientific and technical merit of grant and
cooperative agreement applications received
from academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct research on
exposures to volcanic emissions and
environmental air pollutants.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of cooperative agreement
applications submitted in response to Fiscal
Year 2008 Requests for Applications related
to the following individual research
announcement: E08–001, Program to assess
health effects associated with exposures to
volcanic emissions and environmental air
pollutants.
Agenda items are subject to change as
priorities dictate.
NCIPC determines that agency business
requires its consideration of this matter on
less than 15 days notice to the public and
that no earlier notice of this meeting was
possible.
Contact Person for More Information: J.
Felix Rogers, Ph.D., M.P.H., Telephone
(770)488–4334, NCIPC/ERPO, CDC, 4770
Buford Highway, NE., M/S F62, Atlanta, GA
30341–3724.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: May 8, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–10751 Filed 5–13–08; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Center for Injury Prevention
and Control/ Initial Review Group,
(NCIPC/IRG)
jlentini on PROD1PC65 with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned review group:
Time and Date: 1 p.m.–3 p.m., May 19,
2008 (Closed).
Place: Teleconference.
VerDate Aug<31>2005
16:39 May 13, 2008
Jkt 214001
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
AGENCY:
ACTION:
PO 00000
Notice of Public Meeting.
Frm 00042
Fmt 4703
Sfmt 4703
27835
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the following public
meeting: ‘‘Partnerships to Advance the
National Occupational Research Agenda
(NORA)’’.
Public Meeting Time and Date:
9 a.m.–3 p.m. EDT, June 19, 2008.
Place: Patriots Plaza, 395 E Street,
SW., Conference Room 9000,
Washington, DC 20201.
Purpose of Meeting: The National
Occupational Research Agenda (NORA)
has been structured to engage partners
with each other and/or with NIOSH to
advance NORA priorities. The NORA
Liaison Committee continues to be an
opportunity for representatives from
organizations with national scope to
learn about NORA progress and to
suggest possible partnerships based on
their organization’s mission and
contacts. This opportunity is now
structured as a public meeting via the
Internet to attract participation by a
larger number of organizations and to
further enhance the success of NORA.
Some of the types of organizations of
national scope that are especially
encouraged to participate are employers,
unions, trade associations, labor
associations, professional associations,
and foundations. Others are welcome.
This meeting will include updates
from NIOSH leadership on NORA as
well as updates from approximately half
of the Sector Councils on their progress,
priorities, and implementation plans to
date, including the Construction Sector,
Manufacturing Sector, Services Sector,
Public Safety Sub-Sector, and Wholesale
and Retail Trade Sector. After each
update, there will be time to discuss
partnership opportunities.
Status: The meeting is open to the
public, limited only by the capacities of
the conference call and conference room
facilities. There is limited space
available in the meeting room (capacity
34). Therefore, information to allow
participation in the meeting through the
Internet (to see the slides) and a
teleconference call (capacity 50) will be
provided to registered participants.
Participants are encouraged to consider
attending by this method. Each
participant is requested to register for
the free meeting by sending an e-mail to
noracoordinator@cdc.gov containing the
participant’s name, organization name,
contact phone number on the day of the
meeting, and preference for
participation by Web meeting
(requirements include: computer,
Internet connection, and phone,
preferably with ‘‘mute’’ capability) or in
person. An e-mail confirming
E:\FR\FM\14MYN1.SGM
14MYN1
27836
Federal Register / Vol. 73, No. 94 / Wednesday, May 14, 2008 / Notices
registration will include the details
needed to participate in the web
meeting. Non-US citizens are
encouraged to participate in the web
meeting. Non-US citizens registering to
attend in person after June 2 will not
have time to comply with security
procedures.
Background: NORA is a partnership
program to stimulate innovative
research in occupational safety and
health leading to improved workplace
practices. Unveiled in 1996, NORA has
become a research framework for the
nation. Diverse parties collaborate to
identify the most critical issues in
workplace safety and health. Partners
then work together to develop goals and
objectives for addressing those needs
and to move the research results into
practice. The NIOSH role is facilitator of
the process. For more information about
NORA, see https://www.cdc.gov/niosh/
nora/about.html.
Since 2006, NORA has been
structured by industrial sectors. Eight
sector groups have been defined using
the North American Industrial
Classification System (NAICS). After
receiving public input through the web
and town hall meetings, NORA Sector
Councils have been working to define
sector-specific strategic plans for
conducting research and moving the
results into widespread practice. During
2008, most of these Councils will post
draft strategic plans for public comment.
For more information, see the link above
and choose ‘‘Sector-based Approach,’’
‘‘NORA Sector Councils’’ and
‘‘Comment on Draft Sector Agendas’’
from the right-side menu.
Contact Person for Technical
Information: Sidney C. Soderholm, PhD,
NORA Coordinator, e-mail
noracoordinator@cdc.gov, telephone
(202) 245–0665.
Dated: May 5, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E8–10753 Filed 5–13–08; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
jlentini on PROD1PC65 with NOTICES
Delegation of Authority
Notice is hereby given that I have
redelegated to Charles N.W. Keckler,
Esq., Senior Advisor, Immediate Office
of the Assistant Secretary,
Administration for Children and
Families (ACF), the following authority
VerDate Aug<31>2005
16:39 May 13, 2008
Jkt 214001
vested in the Assistant Secretary for
Children and Families.
(a) Authority Delegated.
Authority to review and make
decisions to approve or disapprove
requests for testimony by ACF
employees or former ACF employees
concerning information acquired in the
course of performing official duties or
because of such persons’ official
capacity with the Department of Health
and Human Services in proceedings
where the United States is not a party.
(b) Limitations and Conditions.
This redelegation may not be further
redelegated.
(c) Effect on Existing Delegations.
None.
(d) Effective date.
This redelegation is effective on the
date of signature. I hereby affirm and
ratify any actions taken by Mr. Charles
Keckler which, in effect, involved the
exercise of this authority prior to the
effective date of this redelegation.
Dated: May 2, 2008.
Daniel C. Schneider,
Acting Assistant Secretary for Children and
Families.
[FR Doc. E8–10766 Filed 5–13–08; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–E–0102] (formerly
Docket No. 2007E–0184)
Determination of Regulatory Review
Period for Purposes of Patent
Extension; AVASTIN
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
AVASTIN and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of an
application to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of a patent
which claims that human biological
product.
ADDRESSES: Submit written or electronic
comments and petitions to the Division
of Dockets Management (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD
20852. Submit electronic comments to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human
biological products, the testing phase
begins when the exemption to permit
the clinical investigations of the
biological becomes effective and runs
until the approval phase begins. The
approval phase starts with the initial
submission of an application to market
the human biological product and
continues until FDA grants permission
to market the biological product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human biological product
will include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA approved for marketing the
human biologic product AVASTIN
(bevacizumab). AVASTIN, used in
combination with intravenous 5fluorouracil-based chemotherapy, is
indicated for first-line treatment of
patients with metastatic carcinoma of
the colon or rectum. Subsequent to this
approval, the Patent and Trademark
Office received a patent term restoration
application for AVASTIN (U.S. Patent
No. 6,639,055) from Genentech, Inc.,
and the Patent and Trademark Office
requested FDA’s assistance in
determining this patent’s eligibility for
patent term restoration. In a letter dated
July 24, 2007, FDA advised the Patent
and Trademark Office that this human
biological product had undergone a
regulatory review period and that the
approval of AVASTIN represented the
E:\FR\FM\14MYN1.SGM
14MYN1
Agencies
[Federal Register Volume 73, Number 94 (Wednesday, May 14, 2008)]
[Notices]
[Pages 27835-27836]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-10753]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Meeting
AGENCY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC),
Department of Health and Human Services (HHS).
ACTION: Notice of Public Meeting.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
announces the following public meeting: ``Partnerships to Advance the
National Occupational Research Agenda (NORA)''.
Public Meeting Time and Date: 9 a.m.-3 p.m. EDT, June 19, 2008.
Place: Patriots Plaza, 395 E Street, SW., Conference Room 9000,
Washington, DC 20201.
Purpose of Meeting: The National Occupational Research Agenda
(NORA) has been structured to engage partners with each other and/or
with NIOSH to advance NORA priorities. The NORA Liaison Committee
continues to be an opportunity for representatives from organizations
with national scope to learn about NORA progress and to suggest
possible partnerships based on their organization's mission and
contacts. This opportunity is now structured as a public meeting via
the Internet to attract participation by a larger number of
organizations and to further enhance the success of NORA. Some of the
types of organizations of national scope that are especially encouraged
to participate are employers, unions, trade associations, labor
associations, professional associations, and foundations. Others are
welcome.
This meeting will include updates from NIOSH leadership on NORA as
well as updates from approximately half of the Sector Councils on their
progress, priorities, and implementation plans to date, including the
Construction Sector, Manufacturing Sector, Services Sector, Public
Safety Sub-Sector, and Wholesale and Retail Trade Sector. After each
update, there will be time to discuss partnership opportunities.
Status: The meeting is open to the public, limited only by the
capacities of the conference call and conference room facilities. There
is limited space available in the meeting room (capacity 34).
Therefore, information to allow participation in the meeting through
the Internet (to see the slides) and a teleconference call (capacity
50) will be provided to registered participants. Participants are
encouraged to consider attending by this method. Each participant is
requested to register for the free meeting by sending an e-mail to
noracoordinator@cdc.gov containing the participant's name, organization
name, contact phone number on the day of the meeting, and preference
for participation by Web meeting (requirements include: computer,
Internet connection, and phone, preferably with ``mute'' capability) or
in person. An e-mail confirming
[[Page 27836]]
registration will include the details needed to participate in the web
meeting. Non-US citizens are encouraged to participate in the web
meeting. Non-US citizens registering to attend in person after June 2
will not have time to comply with security procedures.
Background: NORA is a partnership program to stimulate innovative
research in occupational safety and health leading to improved
workplace practices. Unveiled in 1996, NORA has become a research
framework for the nation. Diverse parties collaborate to identify the
most critical issues in workplace safety and health. Partners then work
together to develop goals and objectives for addressing those needs and
to move the research results into practice. The NIOSH role is
facilitator of the process. For more information about NORA, see http:/
/www.cdc.gov/niosh/nora/about.html.
Since 2006, NORA has been structured by industrial sectors. Eight
sector groups have been defined using the North American Industrial
Classification System (NAICS). After receiving public input through the
web and town hall meetings, NORA Sector Councils have been working to
define sector-specific strategic plans for conducting research and
moving the results into widespread practice. During 2008, most of these
Councils will post draft strategic plans for public comment. For more
information, see the link above and choose ``Sector-based Approach,''
``NORA Sector Councils'' and ``Comment on Draft Sector Agendas'' from
the right-side menu.
Contact Person for Technical Information: Sidney C. Soderholm, PhD,
NORA Coordinator, e-mail noracoordinator@cdc.gov, telephone (202) 245-
0665.
Dated: May 5, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E8-10753 Filed 5-13-08; 8:45 am]
BILLING CODE 4163-19-P